Publications
83
Citations
424
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
Soma Mukhopadhyay's work centers on cancer biology, particularly breast, ovarian, colorectal, bladder, and gall bladder cancers, examining molecular pathways like signaling proteins (e.g., thrombin-PAR1, FVIIa-PAR2), microRNAs, and natural compounds (e.g., kaempferol) that influence tumor growth, drug resistance, and immune evasion. The research also includes nanoparticle-based imaging and therapy approaches for cancer, along with some unrelated work on anesthesia/pain management and anatomy education. This body of work would suit students interested in translational cancer research, molecular oncology, or drug resistance mechanisms.
Publication output has grown gradually over the past decade, rising from about 1-2 papers per year in 2017-2020 to a peak of around 5-6 papers per year in 2022-2023, followed by a slight decline in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression
Cancer Letters · 2026
- Differential Expression of miRNAs Between Young-Onset and Late-Onset Indian Colorectal Carcinoma Patients
Non-Coding RNA · 2025
- Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy
Molecular Pharmaceutics · 2024
- FVIIa-PAR2 signaling facilitates immune escape by reducing phagocytic potential of macrophages in breast cancer
Journal of Thrombosis and Haemostasis · 2024
- Corrigendum to “Kaempferol attenuates viability of ex-vivo cultured post-NACT breast tumor explants through downregulation of p53 induced stemness, inflammation and apoptosis evasion pathways” Pathol. - Res. Pract. 237 (2022) 154029
Pathology - Research and Practice · 2024
- Kaempferol with Verapamil impeded panoramic chemoevasion pathways in breast cancer through ROS overproduction and disruption of lysosomal biogenesis
Phytomedicine · 2023
- High-grade serous ovarian carcinoma, the “Achiles’ hill” for clinicians and molecular biologists: a molecular insight
Molecular Biology Reports · 2023
- Synthesis, Characterization, and Biological Evaluation of Radiolabeled Glutamine Conjugated Polymeric Nanoparticles: A Simple Approach for Tumor Imaging
ACS Applied Bio Materials · 2023
- A Comparative Study Between Oral Pregabalin and Gabapentin in Prolongation of Postoperative Pain Relief after Spinal Anaesthesia
Indian Journal of Public Health Research & Development · 2023
- Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer
World Journal of Gastrointestinal Oncology · 2023
- Differential expression of miRNAs between Young-Onset and Late-Onset Indian colorectal carcinoma patients
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil
Toxicology and Applied Pharmacology · 2022
- Kaempferol attenuates viability of ex-vivo cultured post-NACT breast tumor explants through downregulation of p53 induced stemness, inflammation and apoptosis evasion pathways
Pathology - Research and Practice · 2022
- Interplay of gut microbiome, fatty acids, and the endocannabinoid system in regulating development, progression, immunomodulation, and chemoresistance of cancer
Nutrition · 2022
- Combined positive score (CPS) for scoring PD-L1 positivity
Cancer Research Statistics and Treatment · 2022
- Pathology - Research and Practice×2
- Journal of Traditional and Complementary Medicine×2
- Figshare×2
- Toxicology and Applied Pharmacology×1
- Phytomedicine×1
- Brandon M. Hardesty
Medicine · Indiana University
- Christian Rivera
Medicine · Purdue University West Lafayette
- Ben McCorkle
Medicine · The Ohio State University
- Andrew RW O’Brien
Medicine · Indiana University
- Derrick L. Goubeaux
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile